Abstract: The present disclosure is directed to bispecific antibodies which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.

Abstract: Systems and methods for identifying patterns in blockchain activities based on multi-modal data using artificial intelligence models that compensate for training data featuring a high proportion of missing data points. For example, the system may receive blockchain activity record data for a plurality of blockchain activities involving a plurality of blockchain accounts. The system may input the data into an artificial intelligence model, wherein the artificial intelligence model is trained to identify serial relationships of related blockchain activities corresponding to inputted target blockchain activities based on proportions of digital assets at subsets of blockchain accounts of the plurality of blockchain accounts. The system may receive an output from the artificial intelligence model. The system may generate for display, in a user interface, a visualization of the target blockchain activity based on the output.

Abstract: The present disclosure relates generally to the field of medical devices and establishing fluid communication between body lumens. In particular, the present disclosure relates to devices and methods for establishing a controlled flow or access passage between body lumens. For example, a device may include an elongate tubular body defining a lumen along a length thereof. The elongate tubular body may have an unexpanded configuration and an expanded configuration. In the expanded configuration, a proximal portion of the elongate tubular body may expand into a proximal retention member and a distal portion of the elongate tubular body may expand into a distal retention member, leaving a cylindrical saddle region extending therebetween. The cylindrical saddle region may include a constricted portion configured to move between a first diameter configuration and a second diameter configuration larger than the first diameter configuration.

Abstract: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.

Abstract: Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.

Abstract: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.

Abstract: The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.

Abstract: The present disclosure is directed to dual specific antibodies, which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.

Abstract: Disclosed herein are systems and methods for tracking and managing location information for automobile assets. By affixing passive transmitter tags with unique identification information to automobile assets, location information may be associated with designated areas and/or location information by scanning the passive transmitter tags at various scan points. The location and automobile asset information may be stored, read, and updated in a centralized cloud database platform, accessible at varying levels to suppliers, manufacturers, shippers, and others.

Abstract: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.

Abstract: Provided herein are chimeric scavenger receptor where the endogenous binding region is replaced with an antigen-specific binding region to redirect the specificity of the receptor. Also provided are immune cells, such as, for example, monocytes, that are engineered to express the chimeric scavenger receptor. Also provided are methods of treating patients, such as, for example, Alzheimer's patients, by administering the engineered monocytes.